NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/08/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization15,882 mln
Float60.89 mln
Earnings Date08/12/2026
EPS
1.31
Moderate
P / E
20.18
Premium valuation
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-2.85
Likely reliable
1-Year Forecast
37.55
Exceptional upside
Relative Strength
24
/ 100
Significantly lagging
Business Description
Founded in Denmark in 1998, Genmab is a biotechnology company focused on developing antibody-based treatments for cancer and other serious diseases. Its commercial portfolio includes therapies for blood cancers such as multiple myeloma and lymphoma, cervical cancer, thyroid eye disease, multiple sclerosis, and other conditions, with several more treatments in various stages of development targeting solid tumors, blood disorders, and additional cancer types. The company works alongside a broad network of partners, including Johnson & Johnson, Pfizer, AbbVie, Amgen, and BioNTech, among others.
